Company intelligence / Profile preview

Vitae Pharmaceuticals

Fort Washington, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Vitae advanced several novel small molecules to Phase 2, including VTP-38543 for atopic dermatitis (topical LXRβ agonist), VTP-43742 for autoimmune/dermatological indications, VTP-201227 for psoriasis (enzyme inhibitor), and VTP-195183 for oncology (nuclear receptor agonist to mobilize progenitor cells); all showed early favorable safety/tolerability in phase 1 and initial phase 2 proof-of-concept studies

Therapeutic areas: ImmunologyEndocrinologyNephrologyDermatologyCardiovascularOncologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

GlaxoSmithKline

Beyond the preview

Go deeper on Vitae Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitae Pharmaceuticals.

Explore the full profile